当前位置:首页 - 行情中心 - 华兰生物(002007) - 财务分析 - 现金流量表

华兰生物

(002007)

  

流通市值:273.51亿  总市值:318.03亿
流通股本:15.73亿   总股本:18.29亿

现金流量表

报告期2024-09-302024-06-302024-03-312023-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金3,552,444,941.922,295,901,505.781,154,184,261.525,075,292,993.76
收到的税费返还309,649.98309,649.98-11,853.92
收到其他与经营活动有关的现金54,326,821.0231,455,218.7818,577,278.7972,873,951.65
经营活动现金流入的平衡项目0000
经营活动现金流入小计3,607,081,412.922,327,666,374.541,172,761,540.315,148,178,799.33
购买商品、接受劳务支付的现金1,553,707,874.46927,578,583.47530,413,604.371,555,758,240.75
支付给职工以及为职工支付的现金337,389,345.7254,218,543.21144,152,580460,187,211.84
支付的各项税费342,011,232.97236,351,768.18145,759,781.62503,909,131.19
支付其他与经营活动有关的现金914,263,533.24588,181,263.98302,249,100.921,282,485,434.51
经营活动现金流出的平衡项目0000
经营活动现金流出小计3,147,371,986.372,006,330,158.841,122,575,066.913,802,340,018.29
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额459,709,426.55321,336,215.750,186,473.41,345,838,781.04
二、投资活动产生的现金流量:
收回投资收到的现金17,901,290,166.7511,738,687,058.782,071,994,637.446,407,909,630.24
取得投资收益收到的现金141,920,968.1116,215,602.1150,526,012.4887,943,157.89
处置固定资产、无形资产和其他长期资产收回的现金净额769,072.52690,239.88441,207.88204,113,940.6
处置子公司及其他营业单位收到的现金净额1,550,0007,030.28--
投资活动现金流入的平衡项目0000
投资活动现金流入小计18,045,530,207.3711,855,599,931.052,122,961,857.86,699,966,728.73
购建固定资产、无形资产和其他长期资产支付的现金457,425,868.78260,388,845.16110,356,015.61753,411,070.78
投资支付的现金17,569,564,573.6110,424,087,847.622,076,586,208.786,944,833,339.38
支付其他与投资活动有关的现金-362,323.91162,323.91-
投资活动现金流出的平衡项目0000
投资活动现金流出小计18,026,990,442.3910,684,839,016.692,187,104,548.37,698,244,410.16
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额18,539,764.981,170,760,914.36-64,142,690.5-998,277,681.43
三、筹资活动产生的现金流量:
吸收投资收到的现金16,281,00016,281,000-48,070,638
取得借款收到的现金300,000,000300,000,000200,000,000700,000,000
筹资活动现金流入平衡项目0000
筹资活动现金流入小计316,281,000316,281,000200,000,000748,070,638
偿还债务支付的现金250,000,000.01150,000,000.01-600,000,000
分配股利、利润或偿付利息支付的现金586,908,790.4582,717,423.226,280,940.31602,645,246.3
其中:子公司支付给少数股东的股利、利润117,009,000117,009,000-39,003,000
支付其他与筹资活动有关的现金107,167,606.3939,127,951.38380,753.88380,753.88
筹资活动现金流出平衡项目0000
筹资活动现金流出小计944,076,396.8771,845,374.616,661,694.191,203,026,000.18
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-627,795,396.8-455,564,374.61193,338,305.81-454,955,362.18
四、汇率变动对现金及现金等价物的影响-45,954.89-97,151-99,053.9963,317.76
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-149,592,160.161,036,435,604.45179,283,034.72-107,330,944.81
加:期初现金及现金等价物余额989,324,615.51989,324,615.51989,324,615.511,096,655,560.32
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额839,732,455.352,025,760,219.961,168,607,650.23989,324,615.51
补充资料:
净利润-448,775,270.53-1,761,684,894.67
资产减值准备---90,878,652.81
固定资产和投资性房地产折旧-122,405,583.04-247,856,077.89
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-122,405,583.04-247,856,077.89
无形资产摊销-5,731,565.79-11,196,999.64
长期待摊费用摊销-5,469,673.24-14,196,045.55
处置固定资产、无形资产和其他长期资产的损失--122,811.82--44,443,673.01
固定资产报废损失-2,034,397.69-9,714,357.33
公允价值变动损失--19,356,426.44--60,544,227.95
财务费用-8,372,221.48-13,388,622.2
投资损失--67,879,421.27--149,045,587.36
递延所得税--2,746,010.84-12,809,351.19
其中:递延所得税资产减少--741,284.77--11,647,623.77
递延所得税负债增加--2,004,726.07-24,456,974.96
存货的减少--248,989,496.05--316,446,740.83
经营性应收项目的减少-412,483,525.59--302,658,069.41
经营性应付项目的增加--328,732,690.81-7,973,745.97
其他-23,981,670.54-35,324,175.73
现金的期末余额-2,025,760,219.96-989,324,615.51
减:现金的期初余额-989,324,615.51-1,096,655,560.32
公告日期2024-10-302024-08-302024-04-262024-03-30
审计意见(境内)标准无保留意见
TOP↑